Association between Pro12Ala polymorphism and albuminuria in type 2 diabetic nephropathy

Aims/Introduction Diabetic nephropathy (DN) is a complication of diabetes mellitus that is characterized by the gradual loss of kidney function, which results in increased levels of albumin in the urine. The Pro12Ala polymorphism in the peroxisome proliferator‐activated receptor‐γ2 gene has been confirmed to improve insulin sensitivity, but its association with susceptibility to DN in patients with type 2 diabetes remains inconclusive. Materials and Methods To examine whether the Pro12Ala polymorphism leads to the development of DN, a case‐control study was carried out in 554 patients with type 2 diabetes. The genotypes of Pro12Ala polymorphism of the peroxisome proliferator‐activated receptor gamma 2 gene were analyzed by real‐time polymerase chain reaction with TaqMan® probe genotyping assay in all patients. Results The mean age of the study population was 57.7 ± 8.8 years, with average diabetes duration of 12.8 ± 6.9 years. The prevalence of albuminuria was 43.5%. The frequency of genotype Pro12Pro, Pro12Ala and Ala12Ala genotype were 92.6%, 7.0%, 0.4% in our study population, and 90.4%, 8.9% and 0.7% in normal urinary albumin‐to‐creatinine ratio group, respectively. The Ala carriers (Pro12Ala + Ala12Ala) had significantly lower urinary albumin‐to‐creatinine ratio (15.0 vs 20.5 mg/g, P = 0.001) and better renal function (estimated glomerular filtration rate 81.8 [69.8–97.6] vs 78.7 mL/min/1.73 m2 [61.6–96.2]; P = 0.05) compared with those with the genotype Pro12Pro. After adjustment for age, sex and other confounders, the odds ratio of albuminuria for the Ala12 allele was 0.428 (95% confidence interval 0.195–0.940, P = 0.034]). Conclusions Our results suggest that the peroxisome proliferator‐activated receptor gamma 2 Ala12 variant has significant protective effects against albuminuria and DN. The peroxisome proliferator‐activated receptor‐γ2 Ala12 variant has significant protective effects against albuminuria and diabetic nephropathy. These findings suggest that genetic screening can help in the development of personalized therapies for diabetes.